FOSTER CITY, CA--(MARKET WIRE)--Aug 22, 2006 -- Entelos, Inc. (London:ENTL.L - News) today announced a collaboration with Novartis Pharma AG (NYSE:NVS - News) to conduct research in multiple disease areas. Under terms of the agreement, Novartis will provide R&D funding and Entelos will conduct biosimulation research using its PhysioLab® platforms that predict the effects of drugs using ‘virtual patients’. This unique approach will be used by Novartis to support target evaluation, compound optimization, and phase III clinical trial design. Financial terms were not disclosed. “Entelos is very excited to begin working with Novartis, a world leader in the development of innovation-driven prescription medicines,” stated James Karis, president and CEO of Entelos. “The pharmaceutical industry is realizing the benefits of testing targets and drugs in silico before conducting expensive clinical trials.”
The Entelos technology will be used to support Novartis Development sites and will contribute information to support the company’s drug development process from target evaluation to clinical trial design.
About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company which creates computer models of human physiology designed to reduce the risk, time, and cost of drug discovery and development. The Company’s portfolio of proprietary computer models, known as PhysioLab systems, have helped its pharmaceutical customers validate novel drug targets, select and develop compounds, optimize clinical trials, evaluate in-licensing candidates, and better position existing products in competitive markets. Entelos’ teams of life scientists and engineers create populations of ‘virtual patients’ to simulate and systematically investigate, test, and better understand the underlying biology, variability, and differences in disease progression affecting human response. Entelos currently provides scientific expertise in chronic disease areas such as asthma, obesity, diabetes and rheumatoid arthritis, and complex physiological processes such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization. In addition to internal programs, Entelos partners with global pharmaceutical and biotechnology companies.
Contact: Enquiries:
Entelos, Inc. Jill Fujisaki Vice President Investor Relations Tel: +1 650 572 5430 Email Contact
Brunswick Group Justine McIlroy Alex Tweed Jon Coles Tel: +44 207404 5959
Source: Entelos, Inc.
